179 related articles for article (PubMed ID: 33222438)
1. Improving the Stability of EGFR Inhibitor Cobalt(III) Prodrugs.
Mathuber M; Schueffl H; Dömötör O; Karnthaler C; Enyedy ÉA; Heffeter P; Keppler BK; Kowol CR
Inorg Chem; 2020 Dec; 59(23):17794-17810. PubMed ID: 33222438
[TBL] [Abstract][Full Text] [Related]
2. Tumor-targeting of EGFR inhibitors by hypoxia-mediated activation.
Karnthaler-Benbakka C; Groza D; Kryeziu K; Pichler V; Roller A; Berger W; Heffeter P; Kowol CR
Angew Chem Int Ed Engl; 2014 Nov; 53(47):12930-12935. PubMed ID: 25079700
[TBL] [Abstract][Full Text] [Related]
3. Dual targeting of hypoxic and acidic tumor environments with a cobalt(III) chaperone complex.
Yamamoto N; Renfrew AK; Kim BJ; Bryce NS; Hambley TW
J Med Chem; 2012 Dec; 55(24):11013-21. PubMed ID: 23199008
[TBL] [Abstract][Full Text] [Related]
4. Development and biological investigations of hypoxia-sensitive prodrugs of the tyrosine kinase inhibitor crizotinib.
Bielec B; Schueffl H; Terenzi A; Berger W; Heffeter P; Keppler BK; Kowol CR
Bioorg Chem; 2020 Jun; 99():103778. PubMed ID: 32229347
[TBL] [Abstract][Full Text] [Related]
5. Cobalt(III) Chaperone Complexes of Curcumin: Photoreduction, Cellular Accumulation and Light-Selective Toxicity towards Tumour Cells.
Renfrew AK; Bryce NS; Hambley T
Chemistry; 2015 Oct; 21(43):15224-34. PubMed ID: 26471438
[TBL] [Abstract][Full Text] [Related]
6. Cross-bridged cyclen or cyclam Co(III) complexes containing cytotoxic ligands as hypoxia-activated prodrugs.
Chang JY; Lu GL; Stevenson RJ; Brothers PJ; Clark GR; Botting KJ; Ferry DM; Tercel M; Wilson WR; Denny WA; Ware DC
Inorg Chem; 2013 Jul; 52(13):7688-98. PubMed ID: 23773210
[TBL] [Abstract][Full Text] [Related]
7. Syntheses of 8-quinolinolatocobalt(III) complexes containing cyclen based auxiliary ligands as models for hypoxia-activated prodrugs.
Chang JY; Stevenson RJ; Lu GL; Brothers PJ; Clark GR; Denny WA; Ware DC
Dalton Trans; 2010 Dec; 39(48):11535-50. PubMed ID: 21103540
[TBL] [Abstract][Full Text] [Related]
8. Metal complexes bearing EGFR-inhibiting ligands as promising anticancer agents.
Ma X; Wang Z; Li Y; Wang Y; Liu W
Med Res Rev; 2024 Jul; 44(4):1545-1565. PubMed ID: 38279970
[TBL] [Abstract][Full Text] [Related]
9. Investigation of cobalt(iii)-triazole systems as prototypes for hypoxia-activated drug delivery.
de Souza IC; Faro LV; Pinheiro CB; Gonzaga DT; da Silva Fde C; Ferreira VF; Miranda Fda S; Scarpellini M; Lanznaster M
Dalton Trans; 2016 Sep; 45(35):13671-4. PubMed ID: 27488398
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia-Responsive Cobalt Complexes in Tumor Spheroids: Laser Ablation Inductively Coupled Plasma Mass Spectrometry and Magnetic Resonance Imaging Studies.
O'Neill ES; Kaur A; Bishop DP; Shishmarev D; Kuchel PW; Grieve SM; Figtree GA; Renfrew AK; Bonnitcha PD; New EJ
Inorg Chem; 2017 Aug; 56(16):9860-9868. PubMed ID: 28766939
[TBL] [Abstract][Full Text] [Related]
11. A novel EGFR inhibitor acts as potent tool for hypoxia-activated prodrug systems and exerts strong synergistic activity with VEGFR inhibition in vitro and in vivo.
Caban M; Koblmueller B; Groza D; Schueffl HH; Terenzi A; Tolios A; Mohr T; Mathuber M; Kryeziu K; Jaunecker C; Pirker C; Keppler BK; Berger W; Kowol CR; Heffeter P
Cancer Lett; 2023 Jul; 565():216237. PubMed ID: 37211067
[TBL] [Abstract][Full Text] [Related]
12. A study on the properties and reactivity of naphthoquinone-cobalt(III) prototypes for bioreductive prodrugs.
Bustamante FL; Miranda FS; Castro FA; Resende JA; Pereira MD; Lanznaster M
J Inorg Biochem; 2014 Mar; 132():37-44. PubMed ID: 24326134
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, characterization and cytotoxicity studies of Co(III)-flavonolato complexes.
Kozsup M; Zhou X; Farkas E; Bényei AC; Bonnet S; Patonay T; Kónya K; Buglyó P
J Inorg Biochem; 2021 Apr; 217():111382. PubMed ID: 33588278
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of 5-hydroxy-1,4-naphthoquinone-cobalt(III) complexes for hypoxia-activated drug delivery.
de Mello MVP; Cebrián-Torrejón G; Pereira JR; Dos Santos Moreira C; Gomes CBSMR; da Rocha DR; de Souza Fagundes EM; Ferreira GB; Lanznaster M
J Inorg Biochem; 2019 Oct; 199():110756. PubMed ID: 31299378
[TBL] [Abstract][Full Text] [Related]
15. Development of a cobalt(iii)-based ponatinib prodrug system.
Mathuber M; Gutmann M; La Franca M; Vician P; Laemmerer A; Moser P; Keppler BK; Berger W; Kowol CR
Inorg Chem Front; 2021 Mar; 8(10):2468-2485. PubMed ID: 34046181
[TBL] [Abstract][Full Text] [Related]
16. The influence of the ancillary ligand on the potential of cobalt(iii) complexes to act as chaperones for hydroxamic acid-based drugs.
Green BP; Renfrew AK; Glenister A; Turner P; Hambley TW
Dalton Trans; 2017 Nov; 46(45):15897-15907. PubMed ID: 29116280
[TBL] [Abstract][Full Text] [Related]
17. Ruthenium Complexes are pH-Activated Metallo Prodrugs (pHAMPs) with Light-Triggered Selective Toxicity Toward Cancer Cells.
Qu F; Park S; Martinez K; Gray JL; Thowfeik FS; Lundeen JA; Kuhn AE; Charboneau DJ; Gerlach DL; Lockart MM; Law JA; Jernigan KL; Chambers N; Zeller M; Piro NA; Kassel WS; Schmehl RH; Paul JJ; Merino EJ; Kim Y; Papish ET
Inorg Chem; 2017 Jul; 56(13):7519-7532. PubMed ID: 28636344
[TBL] [Abstract][Full Text] [Related]
18. Radiolytic and cellular reduction of a novel hypoxia-activated cobalt(III) prodrug of a chloromethylbenzindoline DNA minor groove alkylator.
Ahn GO; Botting KJ; Patterson AV; Ware DC; Tercel M; Wilson WR
Biochem Pharmacol; 2006 Jun; 71(12):1683-94. PubMed ID: 16620789
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and evaluation of stable bidentate transition metal complexes of 1-(chloromethyl)-5-hydroxy-3-(5,6,7-trimethoxyindol-2-ylcarbonyl)-2,3-dihydro-1H-pyrrolo[3,2-f]quinoline (seco-6-azaCBI-TMI) as hypoxia selective cytotoxins.
Milbank JB; Stevenson RJ; Ware DC; Chang JY; Tercel M; Ahn GO; Wilson WR; Denny WA
J Med Chem; 2009 Nov; 52(21):6822-34. PubMed ID: 19821576
[TBL] [Abstract][Full Text] [Related]
20. EGFR-targeted prodrug activation using bioorthogonal alkene-azide click-and-release chemistry.
Fairhall JM; Camilli JC; Gibson BH; Hook S; Gamble AB
Bioorg Med Chem; 2021 Sep; 46():116361. PubMed ID: 34411983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
